MARKET

CERS

CERS

Cerus
NASDAQ
2.200
+0.060
+2.80%
After Hours: 2.200 0 0.00% 19:12 02/06 EST
OPEN
2.200
PREV CLOSE
2.140
HIGH
2.260
LOW
2.112
VOLUME
1.26M
TURNOVER
--
52 WEEK HIGH
2.955
52 WEEK LOW
1.120
MARKET CAP
422.59M
P/E (TTM)
-25.9434
1D
5D
1M
3M
1Y
5Y
1D
Cerus’ INTERCEPT Platelet Trial Nears Data Phase: Reading the Signals for Investors
TipRanks · 1d ago
Weekly Report: what happened at CERS last week (0126-0130)?
Weekly Report · 5d ago
Weekly Report: what happened at CERS last week (0119-0123)?
Weekly Report · 01/26 09:38
Cerus Director Timothy L. Moore to Step Down After Current Term
Reuters · 01/26 07:30
Cerus announces planned board transition as director departs
TipRanks · 01/23 22:21
Analysts Are Bullish on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Cerus (CERS)
TipRanks · 01/23 16:51
DRK BLOOD DONATION SERVICE BADEN-WÜRTTEMBERG – HESSEN STARTS INITIATE STUDY TO EVALUATE PATHOGEN-INACTIVATED PLATELET CONCENTRATES TREATED WITH CERUS’ INTERCEPT™ BLOOD SYSTEM IN ROUTINE CLINICAL PRACTICE
Reuters · 01/22 12:30
DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus’ INTERCEPT™ Blood System in Routine Clinical Practice
Barchart · 01/22 06:30
More
About CERS
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

Webull offers Cerus Corp stock information, including NASDAQ: CERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CERS stock methods without spending real money on the virtual paper trading platform.